Afatinib use in recurrent epithelial ovarian carcinoma

• Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies. • Targetable mutations may lead to new therapies in gynecologic cancer treatment. • Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors. • Afatinib shows promising respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Shepherd-Littlejohn, Amanda L., Hanft, Wyatt J., Kennedy, Vanessa A., Alvarez, Edwin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639588/
https://www.ncbi.nlm.nih.gov/pubmed/31360743
http://dx.doi.org/10.1016/j.gore.2019.07.001
_version_ 1783436491890884608
author Shepherd-Littlejohn, Amanda L.
Hanft, Wyatt J.
Kennedy, Vanessa A.
Alvarez, Edwin A.
author_facet Shepherd-Littlejohn, Amanda L.
Hanft, Wyatt J.
Kennedy, Vanessa A.
Alvarez, Edwin A.
author_sort Shepherd-Littlejohn, Amanda L.
collection PubMed
description • Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies. • Targetable mutations may lead to new therapies in gynecologic cancer treatment. • Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors. • Afatinib shows promising response rates in lung cancers carrying Her2/neu mutations. • Afatinib may be effective in serous ovarian tumors exhibiting Her2/neu or ERBB2 mutations.
format Online
Article
Text
id pubmed-6639588
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66395882019-07-29 Afatinib use in recurrent epithelial ovarian carcinoma Shepherd-Littlejohn, Amanda L. Hanft, Wyatt J. Kennedy, Vanessa A. Alvarez, Edwin A. Gynecol Oncol Rep Case Report • Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies. • Targetable mutations may lead to new therapies in gynecologic cancer treatment. • Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors. • Afatinib shows promising response rates in lung cancers carrying Her2/neu mutations. • Afatinib may be effective in serous ovarian tumors exhibiting Her2/neu or ERBB2 mutations. Elsevier 2019-07-03 /pmc/articles/PMC6639588/ /pubmed/31360743 http://dx.doi.org/10.1016/j.gore.2019.07.001 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Shepherd-Littlejohn, Amanda L.
Hanft, Wyatt J.
Kennedy, Vanessa A.
Alvarez, Edwin A.
Afatinib use in recurrent epithelial ovarian carcinoma
title Afatinib use in recurrent epithelial ovarian carcinoma
title_full Afatinib use in recurrent epithelial ovarian carcinoma
title_fullStr Afatinib use in recurrent epithelial ovarian carcinoma
title_full_unstemmed Afatinib use in recurrent epithelial ovarian carcinoma
title_short Afatinib use in recurrent epithelial ovarian carcinoma
title_sort afatinib use in recurrent epithelial ovarian carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639588/
https://www.ncbi.nlm.nih.gov/pubmed/31360743
http://dx.doi.org/10.1016/j.gore.2019.07.001
work_keys_str_mv AT shepherdlittlejohnamandal afatinibuseinrecurrentepithelialovariancarcinoma
AT hanftwyattj afatinibuseinrecurrentepithelialovariancarcinoma
AT kennedyvanessaa afatinibuseinrecurrentepithelialovariancarcinoma
AT alvarezedwina afatinibuseinrecurrentepithelialovariancarcinoma

Ejemplares similares